Eton Pharmaceuticals Inc

ETONNASDAQ · USD
63.65USD0.00 (-0.36%)
6610

Eton Pharmaceuticals Inc (ETON) Covered Calls

Eton Pharmaceuticals Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 11.51%, low versus the past year. ETON's highest covered call setup is the $75.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 17.41% out of the money with 4 days to expiration, a 17.49% return until expiration, and a 1,595.59% theoretical annualized return. Across the setups shown, annualized returns run from 60.87% to 1,595.59% at strikes between $65.00 and $85.00, with 4 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running ETON covered calls helps you generate income from Eton Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ETON covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ETON stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ETON covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ETON covered call is worth writing.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

2026-11-20475.0017.410.052.251117.0017.491595.59-0.08+0.20232.20
2026-11-20470.009.580.151.45627.009.82895.64-0.23+0.21831.30
2026-11-20465.001.750.503.90162.002.54231.41-0.78+0.46453.40
2026-12-183270.009.580.703.90682.0010.68121.78-1.10+0.34433.20
2027-02-199580.0025.231.254.501737.0027.19104.47-1.96+0.28323.25
2027-02-199575.0017.412.655.701377.0021.5682.82-4.15+0.376053.05
2027-05-2118685.0033.063.507.402462.0038.5475.63-5.48+0.35133.90
2026-12-183265.001.752.756.00387.006.0669.10-4.30+0.511783.25
2027-05-2118680.0025.234.608.502072.0032.4463.65-7.20+0.4123.90
2027-02-199570.009.584.007.501012.0015.8460.87-6.26+0.463783.50

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank11.51% Low
  • Market cap (M$)1,836
  • 52 weeks high-9.90%
  • 52 weeks low346.04%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$80.75
    26.87% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E42.17
  • Future P/E21.99
  • EPS (ttm)1.51
  • EPS growth next 5 years125.39%

As of Nov 17, 2026